Granules India posts 23 per cent rise in Q3 profit
Consolidated profit rose to Rs 1.24 billion ($15.22 million) for the three months ended 31st December, from Rs 1.01 billion a year…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Granules India
Granules India reports income from operations at Rs 1,030 crores up 29 per cent
YoY, EBITDA at Rs 193 crores, EBITDA margin at 19 per cent; PAT at Rs 111 crores
Granules Pharmaceuticals receives ANDA approval for Amphetamine mixed salts from US FDA
The product is bioequivalent to the Reference Listed Drug (RLD) product Adderall of Teva Women’s Health Inc, and would be…
Granules India gets US FDA nod for generic Prazosin Hydrochloride capsules
These capsules are bioequivalent to the reference listed drug product, Mini plus capsules 1mg, 2mg and 5mg of Pfizer Inc
Granules India and Jubilant Cadista recall products in US market
Granules initiated the Class-II voluntary recall on 11th August this year, while Jubilant commenced the Class-III recall on 21st…
Granules India gets licence from DRDO to manufacture and market COVID-19 drug 2-DG
Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct…
Granules India gets Health Canada nod to market arthritis tablets
The drug will be manufactured at the company's manufacturing facility located in Gagillapur, Hyderabad
Granules Pharmaceuticals clears US FDA audit
The company had undergone the PAI audit by the US Food and Drug Administration (FDA) from 21st June, 2021 to 25th June, 2021
Granules pledges 16 crore Paracetamol tablets to Telangana government to fight COVID-19
The company will provide one crore tablets every week, starting from May 12, 2021, aggregating to 16 crore tablets worth Rs 8…